Key Insights

Highlights

Treatment Research

3 treatments under study, led by Asciminib Hydrochloride

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 1/2 (1)

Trial Status

Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT04925479Phase 1/2RecruitingPrimary

Study to Determine the Dose and Safety of Asciminib in Pediatric Patients With Chronic Myeloid Leukemia

Showing all 1 trials

Research Network

Common Treatments

  • Asciminib Hydrochloride1
  • Asciminib Pediatric Formulation Group1
  • Asciminib Adult Formulation Group1

Active Sponsors

  • Novartis Pharma AG1
  • Novartis Pharmaceuticals1

Related Conditions

  • Pediatric Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia In Chronic Phase Ph Cmlcp Previously Treated With One Or More Tyrosine Kinase Inhibitors1

Activity Timeline